litlas
Log inCreate account

Paul Polakis

Active 1985–2020

72
Papers
26,719
Citations
68
h-index
71
i10-index

Citations

Citations per year for Paul Polakis1986: 1 citations1987: 1 citations1988: 3 citations1989: 4 citations1990: 12 citations1991: 52 citations1992: 67 citations1993: 73 citations1994: 115 citations1995: 118 citations1996: 190 citations1997: 333 citations1998: 347 citations1999: 545 citations2000: 590 citations2001: 587 citations2002: 572 citations2003: 456 citations2004: 467 citations2005: 391 citations2006: 309 citations2007: 239 citations2008: 333 citations2009: 250 citations2010: 207 citations2011: 219 citations2012: 277 citations2013: 236 citations2014: 273 citations2015: 266 citations2016: 217 citations2017: 234 citations2018: 203 citations2019: 624 citations2020: 543 citations2021: 439 citations2022: 303 citations2023: 222 citations2024: 301 citations2025: 157 citations2026: 2 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,498 citing papers, 38% of this breakdownChina: 806 citing papers, 8.8% of this breakdownUnited Kingdom: 623 citing papers, 6.8% of this breakdownGermany: 557 citing papers, 6% of this breakdownJapan: 515 citing papers, 5.6% of this breakdownFrance: 333 citing papers, 3.6% of this breakdownCanada: 298 citing papers, 3.2% of this breakdownNetherlands: 255 citing papers, 2.8% of this breakdownItaly: 189 citing papers, 2% of this breakdownSwitzerland: 181 citing papers, 2% of this breakdownAustralia: 173 citing papers, 1.9% of this breakdownSouth Korea: 163 citing papers, 1.8% of this breakdown
0%38%Other 17.5%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology63.3%
  • Medicine29.3%
  • Neuroscience2.3%
  • Immunology and Microbiology1.8%
  • Chemistry1.2%
  • Materials Science0.7%
  • Other1.4%

Topics

  • Wnt/β-catenin signaling in development and cancer13.1%
  • Cancer-related gene regulation8.7%
  • Monoclonal and Polyclonal Antibodies Research4%
  • HER2/EGFR in Cancer Research3.1%
  • Kruppel-like factors research2.1%
  • Cancer Cells and Metastasis2%
  • Other67%

Coauthors

All papers

Open in search
  1. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

    Authors: Jagath R. Junutula, Helga Raab, Suzanna Clark, Sunil Bhakta, Douglas D. Leipold, Sylvia Weir, Yvonne Chen, Michelle Simpson, Siao Ping Tsai, Mark S. Dennis, Yanmei Lu, Y. Gloria Meng, Carl Ng, Jihong Yang, Chien C Lee, Eileen Duenas, Jeffrey Gorrell, Viswanatham Katta, Amy Kim, Kevin S. McDorman, Kelly M. Flagella, Rayna Venook, Sarajane Ross, Susan D. Spencer, Wai Lee Wong, Henry B. Lowman, Richard Vandlen, Mark X. Sliwkowski, Richard H. Scheller, Paul Polakis, William Mallet - Nature Biotechnology 2008 cited by 1,354

  2. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

    Authors: Ben‐Quan Shen, Keyang Xu, Luna Liu, Helga Raab, Sunil Bhakta, Margaret Kenrick, Kathryn Parsons-Reponte, Janet Tien, Shang‐Fan Yu, Elaine Mai, Dongwei Li, Jay Tibbitts, Jakub Baudys, Ola M. Saad, Suzie J. Scales, Paul J McDonald, Philip E. Hass, Charles Eigenbrot, Trung Van Nguyen, Willy A. Solis, Reina N. Fuji, Kelly M. Flagella, Darshana Patel, Susan D. Spencer, Leslie A. Khawli, Allen Ebens, Wai Lee Wong, Richard Vandlen, Surinder Kaur, Mark X. Sliwkowski, Richard H. Scheller, Paul Polakis, Jagath R. Junutula - Nature Biotechnology 2012 cited by 999

  3. Site-specific antibody drug conjugates for cancer therapy

    Authors: Siler H. Panowski, Sunil Bhakta, Helga Raab, Paul Polakis, Jagath R. Junutula - mAbs 2013 cited by 658

  4. A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs

    Authors: Shang‐Fan Yu, Bing Zheng, MaryAnn Go, Jeffrey Lau, Susan D. Spencer, Helga Raab, Robert Soriano, Suchit Jhunjhunwala, Robert Cohen, Michele Caruso, Paul Polakis, John A. Flygare, Andrew G. Polson - Clinical Cancer Research 2015 cited by 162

  5. Targeting LGR5 + cells with an antibody-drug conjugate for the treatment of colon cancer

    Authors: Melissa R. Junttila, Weiguang Mao, Xi Wang, Bu-Er Wang, Thinh Pham, John A. Flygare, Shang‐Fan Yu, Sharon Yee, David M. Goldenberg, Carter T. Fields, Jeffrey Eastham‐Anderson, Mallika Singh, Rajesh Vij, Jo-Anne Hongo, Ron Firestein, Melissa M. Schutten, Kelly M. Flagella, Paul Polakis, Andrew G. Polson - Science Translational Medicine 2015 cited by 186

  6. Wnt Signaling in Cancer

    Authors: Paul Polakis - Cold Spring Harbor Perspectives in Biology 2012 cited by 851

  7. A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth

    Authors: Ted Lau, Emily Chan, Marinella Callow, Jo Waaler, Jason Boggs, Robert A. Blake, Steven Magnuson, Amy Sambrone, Melissa M. Schutten, Ron Firestein, Ondřej Machoň, Vladimír Kořínek, Edna F. Choo, Dolores Diaz, Mark Merchant, Paul Polakis, Daniel D. Holsworth, Stefan Krauß, Mike Costa - Cancer Research 2013 cited by 320

  8. Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly

    Authors: Bonnee Rubinfeld, Iris Albert, Emilio Porfiri, Carol J. Fiol, S Munemitsu, Paul Polakis - Science 1996 cited by 1,421

  9. Ubiquitin Ligase RNF146 Regulates Tankyrase and Axin to Promote Wnt Signaling

    Authors: Marinella Callow, Hoanh Tran, Lilian Phu, Ted Lau, James Lee, Wendy Sandoval, Peter S. Liu, Sheila Bheddah, Janet Tao, Jennie R. Lill, Jo-Anne Hongo, David Davis, Donald S. Kirkpatrick, Paul Polakis, Mike Costa - PLoS ONE 2011 cited by 225

  10. Wnt signaling and cancer

    Authors: Paul Polakis - Genes & Development 2000 cited by 3,173

  11. Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

    Authors: Jagath R. Junutula, Kelly M. Flagella, Richard Graham, Kathryn L. Parsons, Edward Ha, Helga Raab, Sunil Bhakta, Trung Van Nguyen, Debra L. Dugger, Guangmin Li, Elaine Mai, Gail D. Lewis Phillips, Hajime Hiraragi, Reina N. Fuji, Jay Tibbitts, Richard Vandlen, Susan D. Spencer, Richard H. Scheller, Paul Polakis, Mark X. Sliwkowski - Clinical Cancer Research 2010 cited by 292

  12. Downregulation of β-catenin by human Axin and its association with the APC tumor suppressor, β-catenin and GSK3β

    Authors: Matthew J. Hart, Rico de los Santos, Iris Albert, Bonnee Rubinfeld, Paul Polakis - Current Biology 1998 cited by 845

  13. Antibody Drug Conjugates for Cancer Therapy

    Authors: Paul Polakis - Pharmacological Reviews 2015 cited by 300

  14. Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody–Drug Conjugate as a Therapeutic for Non–Small Cell Lung and Ovarian Cancers

    Authors: Kedan Lin, Bonnee Rubinfeld, Crystal Zhang, Ron Firestein, Eric B. Harstad, Leslie Roth, Siao Ping Tsai, Melissa M. Schutten, Keyang Xu, Maria Hristopoulos, Paul Polakis - Clinical Cancer Research 2015 cited by 93

  15. Stabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines

    Authors: Bonnee Rubinfeld, Paul F. Robbins, Mona El‐Gamil, Iris Albert, Emilio Porfiri, Paul Polakis - Science 1997 cited by 1,223

  16. The F-box protein β-TrCP associates with phosphorylated β-catenin and regulates its activity in the cell

    Authors: Matthew J. Hart, Jean‐Paul Concordet, Irina Lassot, Iris Albert, Robson Santos, Hervé Durand, Christine Perret, Bonnee Rubinfeld, Florence Margottin-Goguet, Richard Bénarous, Paul Polakis - Current Biology 1999 cited by 670

  17. High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers

    Authors: Rachana Ohri, Sunil Bhakta, Aimee Fourie-O’Donohue, Josefa dela Cruz-Chuh, Siao Ping Tsai, Ryan Cook, BinQing Wei, Carl Ng, Athena W. Wong, Aaron B. Bos, Farzam Farahi, Jiten Bhakta, Thomas H. Pillow, Helga Raab, Richard Vandlen, Paul Polakis, Yichin Liu, Hans K. Erickson, Jagath R. Junutula, Katherine R. Kozak - Bioconjugate Chemistry 2018 cited by 113

  18. The many ways of Wnt in cancer

    Authors: Paul Polakis - Current Opinion in Genetics & Development 2007 cited by 863

  19. Site-Specific Trastuzumab Maytansinoid Antibody–Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering

    Authors: Thomas H. Pillow, Janet Tien, Kathryn Parsons-Reponte, Sunil Bhakta, Hao Li, Leanna R. Staben, Guangmin Li, Josefa Chuh, Aimee Fourie-O’Donohue, Martine Darwish, Victor Yip, Luna Liu, Douglas D. Leipold, Dian Su, Elmer Wu, Susan D. Spencer, Ben‐Quan Shen, Keyang Xu, Katherine R. Kozak, Helga Raab, Richard Vandlen, Gail D. Lewis Phillips, Richard H. Scheller, Paul Polakis, Mark X. Sliwkowski, John A. Flygare, Jagath R. Junutula - Journal of Medicinal Chemistry 2014 cited by 106

  20. Structural basis of the Axin–adenomatous polyposis coli interaction

    Authors: K.E. Spink, Paul Polakis, William I. Weis - The EMBO Journal 2000 cited by 207

  21. Wnt Isoform-Specific Interactions with Coreceptor Specify Inhibition or Potentiation of Signaling by LRP6 Antibodies

    Authors: Yan Gong, Eric Bourhis, Cecilia Chiu, Scott Stawicki, Venita DeAlmeida, Bob Y. Liu, Khanhky Phamluong, Tim C. Cao, Richard A.D. Carano, James A. Ernst, Mark J. Solloway, Bonnee Rubinfeld, Rami N. Hannoush, Yan Wu, Paul Polakis, Mike Costa - PLoS ONE 2010 cited by 206

  22. Wnt Signaling in Oncogenesis and Embryogenesis-a Look Outside the Nucleus

    Authors: Mark Peifer, Paul Polakis - Science 2000 cited by 1,254

  23. Phosphorylation of Dishevelled by Protein Kinase RIPK4 Regulates Wnt Signaling

    Authors: XiaoDong Huang, James C. McGann, Bob Y. Liu, Rami N. Hannoush, Jennie R. Lill, Victoria C. Pham, Kim Newton, Michael Kakunda, Jinfeng Liu, Christine Yu, S.G. Hymowitz, Jo-Anne Hongo, Anthony Wynshaw‐Boris, Paul Polakis, Richard M. Harland, Vishva M. Dixit - Science 2013 cited by 111

  24. A GSK3‐binding peptide from FRAT1 selectively inhibits the GSK3‐catalysed phosphorylation of Axin and β‐catenin

    Authors: Gareth M. Thomas, Sheelagh Frame, Michel Goedert, Inke Näthke, Paul Polakis, Philip Cohen - FEBS Letters 1999 cited by 230